Profile data is unavailable for this security.
About the company
Medincell SA is a France-based manufacturer of biological products and pharmaceutical preparations. The Company is focused on the development of therapeutic solutions with worldwide access. The Company works on both for-profit and non-profit projects, in collaboration with partners ranging from pharmaceutical corporations to physicians, from biotechnology firms to academics and foundations. Its range of products consists of three products in development phase: mdc-IRM, a subcutaneous injection in phase III clinical study for the treatment of schizophrenia; mdc-CWM, an intra-articular injection in phase II clinical study for the treatment of post-surgical pain and inflammation; mdc-TJK, a subcutaneous injection for the treatment of schizophrenia, as well as a number of other products that are in the research phase, such as mdc-WWM, which is a subcutaneous injection for contraception, and mdc-ELK, a subcutaneous injection for the treatment of depression, among others.
- Revenue in EUR (TTM)9.03m
- Net income in EUR-25.04m
- Incorporated2002
- Employees134.00
- LocationMedincell SA3 rue des Freres LumiereJACOU 34830FranceFRA
- Phone+33 467021367
- Websitehttps://www.medincell.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Jeena Sikho Lifecare Ltd | -1.09bn | -1.09bn | 426.50m | 1.23k | -- | 123.84 | -- | -- | -- | -- | -- | 12.72 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 0.8228 | -- | 0.2681 | -- | 43.84 | -- | 77.37 | -- | -- | -- |
| Clinuvel Pharmaceuticals Limited | 58.87m | 21.97m | 428.01m | 16.00 | 19.77 | 3.42 | 18.88 | 7.27 | 0.7014 | 0.7014 | 1.87 | 4.05 | 0.4496 | -0.1099 | 3.94 | -- | 16.78 | 18.81 | 19.05 | 21.04 | 101.16 | 102.61 | 37.31 | 39.00 | 8.39 | 10.94 | 0.0043 | 7.42 | 16.15 | 24.75 | 16.44 | 14.47 | 84.96 | 14.87 |
| Gufic BioSciences Ltd | 88.72m | 9.41m | 428.73m | 1.45k | 45.13 | -- | 38.04 | 4.83 | 8.70 | 8.70 | 81.95 | -- | -- | -- | -- | 5,624,707.00 | -- | 11.46 | -- | 19.21 | 52.39 | 45.79 | 10.60 | 10.46 | -- | 8.09 | -- | 1.31 | 16.80 | 18.12 | 8.07 | 31.46 | 53.83 | 14.87 |
| SIGA Technologies Inc | 158.16m | 76.79m | 430.74m | 45.00 | 5.68 | 2.81 | 5.57 | 2.72 | 1.16 | 1.16 | 2.41 | 2.35 | 1.02 | 0.5866 | 23.09 | 3,843,484.00 | 49.52 | 22.34 | 56.21 | 27.56 | 82.00 | 88.65 | 48.55 | 41.14 | 5.65 | -- | 0.00 | 29.51 | 26.31 | -21.75 | 100.76 | -30.57 | -26.67 | -- |
| Botanix Pharmaceuticals Ltd | 417.66k | -8.55m | 431.33m | 1.00 | -- | 6.41 | -- | 1,032.74 | -0.0092 | -0.0092 | 0.0005 | 0.0601 | 0.0099 | -- | 1.59 | -- | -20.20 | -38.81 | -21.07 | -43.07 | -- | -- | -2,047.07 | -4,857.59 | 21.89 | -- | 0.00 | -- | 301.17 | 28.31 | -51.52 | -- | 323.01 | -- |
| Kalvista Pharmaceuticals Inc | 0.00 | -129.64m | 434.31m | 150.00 | -- | 2.74 | -- | -- | -3.54 | -3.54 | 0.00 | 4.01 | 0.00 | -- | -- | 0.00 | -78.65 | -40.63 | -87.52 | -43.67 | -- | -- | -- | -2,972.81 | -- | -- | 0.00 | -- | -- | -- | -36.31 | -- | -16.34 | -- |
| Medincell SA | 9.03m | -25.04m | 436.55m | 134.00 | -- | -- | -- | 48.33 | -0.8754 | -0.8754 | 0.3178 | -1.40 | 0.2725 | -- | 5.99 | 67,402.98 | -75.54 | -61.75 | -- | -167.61 | 74.92 | 71.74 | -277.21 | -366.40 | -- | -5.23 | 3.25 | -- | -8.67 | 44.33 | 21.78 | -- | 9.57 | -- |
| Canopy Growth Corp | 191.07m | -400.84m | 437.42m | 1.03k | -- | 0.8299 | -- | 2.29 | -7.53 | -9.58 | 3.55 | 6.58 | 0.1652 | 1.75 | 4.22 | 279,008.80 | -34.65 | -26.08 | -41.36 | -28.67 | 31.06 | 2.59 | -209.79 | -333.29 | 1.64 | -0.2957 | 0.5392 | -- | -10.83 | 5.59 | 84.29 | -- | -64.60 | -- |
| Cuorips Inc | 119.33k | -4.05m | 440.10m | 59.00 | -- | 12.26 | -- | 3,688.01 | -88.11 | -88.11 | 2.60 | 729.16 | 0.0032 | 1.15 | 10.60 | 328,610.20 | -10.89 | -- | -11.14 | -- | 44.66 | -- | -3,394.40 | -- | 35.37 | -- | 0.00 | -- | -39.65 | -- | -39.84 | -- | -- | -- |
| YungShin Global Holding Corp | 210.92m | 29.86m | 447.31m | 1.57k | 14.98 | 2.14 | 11.10 | 2.12 | 3.95 | 3.95 | 27.91 | 27.66 | 0.5953 | 1.47 | 5.51 | -- | 9.10 | 6.64 | 13.58 | 10.20 | 43.28 | 45.11 | 15.29 | 10.45 | 1.35 | -- | 0.1034 | 70.94 | -3.88 | -1.33 | -1.40 | 3.34 | -29.00 | 0.893 |
| Obio Technology Shanghai Corp Ltd | 30.24m | -25.38m | 448.23m | 731.00 | -- | 1.79 | -- | 14.82 | -0.3052 | -0.3052 | 0.3624 | 3.00 | 0.0938 | 3.61 | 2.37 | 320,267.70 | -7.88 | 0.2246 | -8.68 | 0.2514 | -19.93 | 36.72 | -84.03 | 1.48 | 2.14 | -- | 0.1128 | 0.00 | -29.69 | 35.88 | -425.90 | -- | 57.00 | -- |
| Katakura Industries Co., Ltd. | 240.09m | 17.87m | 449.54m | 1.04k | 23.62 | 0.8919 | 12.63 | 1.87 | 87.82 | 87.82 | 1,179.69 | 2,325.40 | 0.2783 | 2.21 | 5.10 | 37,506,730.00 | 2.19 | 2.35 | 2.82 | 3.34 | 38.25 | 37.75 | 7.87 | 8.32 | 2.71 | -- | 0.1076 | 18.81 | 16.62 | -2.04 | 8.09 | 18.87 | -7.46 | 10.76 |
Data as of Oct 11 2024. Currency figures normalised to Medincell SA's reporting currency: Euro EUR
17.61%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Mirova SA (Investment Management)as of 30 Jun 2023 | 2.27m | 7.81% |
| Syquant Capital SASas of 31 Dec 2023 | 728.73k | 2.51% |
| Polar Capital LLPas of 28 Jun 2024 | 626.02k | 2.15% |
| Amundi Asset Management SA (Investment Management)as of 28 Jun 2024 | 346.44k | 1.19% |
| BFT Investment Managers SAas of 28 Jun 2024 | 322.87k | 1.11% |
| Saint Olive Gestion SNCas of 28 Jun 2024 | 275.15k | 0.95% |
| Mandarine Gestion SAas of 29 Feb 2024 | 155.50k | 0.54% |
| SG 29 Haussmann SASUas of 07 Aug 2024 | 139.00k | 0.48% |
| Montpensier Finance SASas of 29 Dec 2023 | 133.60k | 0.46% |
| Soci�t� G�n�rale Gestion SAas of 28 Jun 2024 | 123.49k | 0.42% |
More ▼
Data from 29 Dec 2023 - 08 Aug 2024Source: FactSet Research Systems Inc.
